All In Biotech

NDA 022303 · Cephalon

Treanda

Bendamustine Hydrochloride · Injection

Last checked: Nov 20, 2026Latest source record: Oct 31, 2008 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Oct 31, 2008

Approved uses

1

Original approval plus efficacy supplements

Registered trials

426

81 Phase 3, 51 recruiting

FAERS reports

11,430

9,922 serious, 2,006 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 31, 2008 Original approval · Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval LabelReviewSummary Review
1 products under this application
  • TREANDA · BENDAMUSTINE HYDROCHLORIDE 100MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Bendamustine" as an intervention, any sponsor and status, largest first.

All 426 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,082
  • pyrexia842
  • disease progression569
  • febrile neutropenia522
  • rash516
  • neutropenia487
  • pneumonia458
  • drug ineffective438
  • platelet count decreased435
  • neutrophil count decreased418
  • product use in unapproved indication411
  • covid-19406

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200856
2009180
2010293
2011278
20121,407
2013512
2014473
2015628
2016554
2017534
2018683
2019640
2020654
2021752
20221,463
20231,034
2024755
2025301
2026233

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Treanda (Bendamustine HCl)

2024 spending

$1.6M

Beneficiaries

50

213 claims

Per beneficiary

$31,188

$2,207.79 per unit

View as table
YearSpending
2020$1,622,385
2021$1,907,188
2022$2,101,803
2023$1,464,634
2024$1,559,402

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 385 on PubMed

Sponsor: Cephalon

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.